AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Von Hippel-Lindau Disease

Recent research efforts aimed at curing Von Hippel-Lindau Disease.

Last updated

Von Hippel-Lindau Disease

Overview

Von Hippel-Lindau disease (VHL) is a rare, inherited cancer-predisposition syndrome caused by a harmful variant in the VHL tumor-suppressor gene. It is usually inherited in an autosomal-dominant pattern, although about 20% of cases arise newly in the affected person; each child of an affected individual has a 50% chance of inheriting the variant. VHL can cause tumors and cysts in the kidneys, brain and spinal cord, retina, pancreas, adrenal glands, and inner ear. Disease severity is highly variable, but kidney clear-cell renal cell carcinoma is a leading cause of VHL-related mortality and occurs in roughly 70% of affected people by age 60. GeneReviews: Von Hippel-Lindau Syndrome

There is not currently a therapy that corrects the inherited VHL variant throughout the body and permanently cures VHL. Standard care is lifelong, multidisciplinary surveillance—regular eye examinations, brain and spine magnetic-resonance imaging (MRI), abdominal imaging, biochemical screening for pheochromocytoma, and hearing assessment—combined with surgery, ablation, laser treatment, or radiation when individual lesions threaten organ function. Surveillance and earlier intervention have substantially improved outcomes, while the HIF-2α inhibitor belzutifan is now a systemic option for certain VHL-associated tumors that do not require immediate surgery. GeneReviews: Von Hippel-Lindau Syndrome

Scope of Recent Research (2020–present)

Research since 2020 has been active but concentrated overwhelmingly on preventing or shrinking VHL-associated tumors rather than repairing the underlying inherited mutation. The dominant question has been whether inhibiting hypoxia-inducible factor 2α (HIF-2α), a protein abnormally activated after loss of VHL function, can delay repeated surgery while controlling tumors in several organs. This has produced a major disease-modifying advance with belzutifan, but the field remains far from a genetic cure because no clinical gene-replacement, RNA-repair, or genome-editing treatment has yet demonstrated correction of VHL disease in patients. Belzutifan for VHL renal cell carcinoma Saturation genome editing of VHL alleles

Major Breakthroughs and Emerging Therapies

The central therapeutic breakthrough has been direct targeting of HIF-2α. Normally, the VHL protein helps cells dispose of HIF proteins when oxygen is available; when VHL function is lost, HIF-2α remains active and promotes abnormal blood-vessel growth and tumor development. Belzutifan is an oral small molecule that blocks HIF-2α activity downstream of the defective gene rather than replacing the gene itself. Belzutifan for VHL renal cell carcinoma

In the pivotal single-arm phase 2 LITESPARK-004 study, belzutifan produced objective responses in 49% of 61 adults with VHL-associated renal cell carcinoma after a median 21.8 months of follow-up. Responses were also reported in pancreatic lesions, central nervous system hemangioblastomas, and retinal hemangioblastomas, establishing the first systemic medicine able to address several VHL tumor types simultaneously. Belzutifan for VHL renal cell carcinoma

Longer follow-up has strengthened the case that HIF-2α inhibition can provide durable tumor control. At approximately 50 months of follow-up in LITESPARK-004, the renal-cell-carcinoma objective-response rate had risen from 49% to 67%, consistent with some responses occurring late during continuous treatment. In the CNS hemangioblastoma subgroup, an updated analysis reported objective responses in 22 of 50 patients when both solid tumors and associated cysts were assessed, with activity sustained beyond three years. LITESPARK-004 50-month follow-up Belzutifan for CNS hemangioblastomas

Gene correction remains an early scientific rather than clinical therapeutic strategy. A 2024 saturation genome-editing study used CRISPR-based editing and next-generation sequencing to measure the functional effects of thousands of possible VHL sequence changes in human cells, helping distinguish harmful variants from uncertain ones and revealing variant-specific biology. This type of work could improve diagnosis, genetic counseling, and eventually the design of mutation-tailored therapies, but it is not itself a treatment and does not solve the delivery, safety, and whole-body editing challenges required for a VHL cure. Saturation genome editing of VHL alleles

Clinical Trials and Experimental Approaches

The key completed-enrollment but ongoing study is Merck Sharp & Dohme’s phase 2 LITESPARK-004 trial, NCT03401788, which tested belzutifan 120 mg daily in adults with germline VHL variants, localized renal tumors not requiring immediate surgery, and no prior systemic anticancer treatment. The study was supported by Merck, the NIH National Cancer Institute’s Center for Cancer Research, and an NCI grant; its results supported regulatory approval of belzutifan for eligible adults with VHL-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors. LITESPARK-004 trial record Belzutifan for VHL renal cell carcinoma

Other studies are testing how belzutifan performs in broader, real-world, and international VHL populations. Merck’s phase 2 LITESPARK-015 study, NCT04924075, includes a cohort for VHL-associated tumors, while the prospective BELIEVE-VHL study, NCT07167329, plans to assess effectiveness, adverse effects, pharmacogenetics, disease progression, and quality of life in 100 patients. A 2026 interim report from the China and Japan VHL cohort of LITESPARK-015 described an 88.2% renal-tumor objective-response rate among 44 treated participants at a median 25.1 months of follow-up; these results are encouraging but remain conference-reported, nonrandomized data. LITESPARK-015 trial record BELIEVE-VHL trial record LITESPARK-015 China and Japan cohort

Methodologies and Scientific Approaches

Clinical research relies on serial, organ-specific imaging and standardized tumor-response measurements. LITESPARK-004 used independent radiology review and RECIST criteria for measurable renal tumors, while dedicated CNS analyses assessed both solid hemangioblastomas and their associated cysts because cyst-related pressure can drive neurological symptoms. These approaches aim to determine not only whether a lesion shrinks, but also whether treatment can safely postpone surgery or radiation. Belzutifan for VHL renal cell carcinoma Belzutifan for CNS hemangioblastomas

Laboratory work combines human cell models, CRISPR perturbation, high-throughput sequencing, and functional classification of individual VHL variants. Saturation genome editing is particularly useful because it can test many possible single-letter DNA changes in parallel and quantify their effects on cell fitness and RNA processing. This creates a foundation for more precise disease models and for identifying which mutations might eventually be amenable to gene repair or other personalized approaches. Saturation genome editing of VHL alleles

Leading Institutions and Funding

The most visible clinical-development partnership has involved Merck Sharp & Dohme, which sponsors the belzutifan trials, together with investigators at major VHL and kidney-cancer centers in the United States and Europe. The LITESPARK-004 program also received support from the NIH Intramural Research Program, the National Cancer Institute Center for Cancer Research, and NCI grant UO1 CA236489. Belzutifan for VHL renal cell carcinoma

Patient-led funding is also important in this rare disease. The VHL Alliance reports awarding more than $3 million in research grants since its founding and currently offers pilot grants of $25,000 for one year plus research and postdoctoral-fellowship grants of $100,000 over two years. Recent grantees have included researchers at the University of Freiburg, Francis Crick Institute, University of Utah, UCLA, MD Anderson Cancer Center, and other institutions. VHL Alliance research grants

Strengths, Limitations, and Challenges

Belzutifan is a major strength of the current research landscape because one oral drug can affect tumors in multiple VHL-affected organs, potentially reducing cumulative surgical burden. The evidence is now supported by several years of follow-up, including sustained CNS hemangioblastoma activity. However, LITESPARK-004 was a small, single-arm study of selected adults whose tumors did not require immediate surgery, so it cannot fully establish how belzutifan compares with surveillance, surgery, or other treatments across all VHL manifestations and age groups. LITESPARK-004 50-month follow-up Belzutifan for CNS hemangioblastomas

The principal limitations are that belzutifan suppresses a downstream disease pathway rather than removing the inherited mutation, and treatment may need to be prolonged. Anemia and fatigue were common in the original VHL trial, and the prescribing information also warns about hypoxia, embryo-fetal toxicity, and the need for monitoring and dose modifications in some patients. The remaining curative challenge is formidable: a true gene-based cure would need to safely restore or correct VHL function in enough relevant cells across several organs without causing harmful off-target changes, immune reactions, or cancer-promoting effects. Belzutifan for VHL renal cell carcinoma FDA prescribing information for belzutifan GeneReviews: Von Hippel-Lindau Syndrome

Outlook and Future Directions

VHL is not close to a definitive genetic cure as of August 8, 2026, but it is substantially closer to long-term medical control than it was in 2020 because HIF-2α inhibition can shrink or stabilize several tumor types at once. The most important near-term milestones are mature long-term safety and treatment-discontinuation data for belzutifan, evidence on whether it meaningfully reduces lifetime surgery and preserves kidney, neurological, and visual function, results in broader international and real-world cohorts, and advances that translate VHL variant-function maps into safe gene- or RNA-based corrective therapies. LITESPARK-004 50-month follow-up BELIEVE-VHL trial record Saturation genome editing of VHL alleles

References

Don't see your disease? Request a report